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This editorial makes reference to the following study:  
Attar R, Valentin JB, Freeman P, Andell P, Aagaard J, Jensen SE. The Effect of 
Schizophrenia on Major Adverse Cardiac Events, Length of Hospital Stay and Prevalence of 
Somatic Comorbidities Following Acute Coronary Syndrome. Eur Heart J Qual Care Clin 
Outcomes 2018. 
 
 
  
Mental health and cardiovascular disorders form two of the biggest expenditures in 
healthcare budgets in the Western world1. The interplay between the two is increasingly 
recognized in the academic literature, yet national and international guidelines tackling this 
directly are lacking. Schizophrenia is a particularly challenging mental health disorder which 
leaves its sufferers with a substantial degree of disability and higher rates of mortality. A 
number of meta-analyses have described a risk of death of up to three-fold compared to the 
general population2, 3.  In fact, studies have described a shorter life expectancy for 
schizophrenia sufferers of approximately 15-25 years2, 4. This does not appear to be changing 
over time with studies showing similar rates between 1996 and 20065. More recent studies 
from Nordic countries have shown similar trends in 20132. Interestingly, the leading cause of 
death in this group is cardiovascular disease in both males and females4.  
 
In the study published by Attar et al6, routinely collected data from nationwide registries 
were utilised to investigate the relationship between schizophrenia and acute coronary 
syndrome (ACS). The advantage of using this resource is to reflect what typically happens in 
our day-to-day clinical practice; also referred to in the literature as ‘real life’. They identified 
726 patients with schizophrenia who experienced an ACS and matched them on a 1:2 basis for 
comorbidities and risk factors with ‘psychiatric healthy controls’ (PHC) with ACS. This serves 
to adjust, at least partially, for the higher inherent risks that patients with schizophrenia 
experience. The study revealed significantly higher major adverse cardiac events (MACE) in 
patients with schizophrenia, driven predominantly by mortality and stroke. This is consistent 
with previous studies that have shown an association between schizophrenia and poor 
outcomes in cardiovascular disease despite adjusting for baseline factors7.  
 
The strengths of this study relate to the relatively large sample size which was used to 
examine this association. The use of ICD-10 codes allows for comprehensive documentation 
of cardiac risk factors and comorbidities, as well as statistical matching and adjusting for these. 
This reduces selection bias, which may accompany carefully selected clinical trial groups. Of 
course however, the study shares similar limitations with other registry studies, where 
unavailable or incomplete data entry limits its accuracy. Furthermore, despite matching for 
ICD-10 diagnoses, there may be other factors not recorded in the routinely collected data set 
that may confound the study, including life style factors such as smoking. In addition, analysis 
of large sets of data on the basis of ICD-10 diagnoses does not allow grading of the severity of 
such conditions, which may in turn influence outcomes. Finally, it is only possible to infer 
associations from these findings and not causation.  
 
The prevalence of cardiovascular disease and its risk factors is high in patients with 
schizophrenia. This has been shown in a number of studies published in both psychiatric and 
cardiovascular journals. For instance, the prevalence of metabolic syndrome in patients with 
schizophrenia has been observed to be more than 40% in both males and females8. These rates 
are much higher (up to 4 fold) than the general population8. The components that make up this 
syndrome are hypertension, dyslipidaemia, obesity and fasting glycaemia – all of which have 
been shown to be individually elevated in this disease group above national averages. 
Furthermore, the prevalence of other risk factors such as diabetes mellitus is at least twice as 
high as in the general population8.  
 
The literature has attributed the higher prevalence of cardiac risk factors to behavioural, 
socioeconomic and healthcare reasons4. These reasons are likely to interact and adversely 
affect each other, further complicating the picture. Behavioural risk factors include unhealthy 
habits which are more prevalent in this patient group, such as tobacco smoking and substance 
abuse4. Patients with schizophrenia have also been shown to be more likely to lead a sedentary 
lifestyle compared to the general population by spending fewer leisurely hours on sports and 
more hours on sedentary activities9. Socioeconomic factors include poor education and poverty 
which in turn compound the behavioural risks. Healthcare factors have been implicated in both 
prevention of risk factors and treatment of acute coronary syndrome in patients with severe 
mental illness. For instance, documentation and treatment of cardiovascular risk factors has 
been shown to be poorly done for patients with schizophrenia10, 11. This could relate to patient 
factors in seeking health care, although patients with severe mental illness have been shown 
not to receive the same level of assessment for physical problems compared to those without 
mental illness11. Other healthcare factors include side effects from anti-psychotic medications 
which are recognized as contributors to the development of obesity, metabolic syndrome and 
possibly autonomic nervous system dysfunction4. To add insult to injury, patients suffering 
from schizophrenia who experience an ACS have been noted to receive suboptimal medical 
care and are half as likely to undergo coronary revascularisation compared to patients with no 
mental illness12, 13. This strongly highlights healthcare inequality when it comes to cardiac 
management and augments the problem by creating a ‘health care paradox’, where patients 
who need care the most, are less likely to receive it.  This paradox could explain the observation 
of multiple studies, including the study by Attar et al, which showed that even after adjusting 
for ICD-10 baseline comorbidities and risk factors, outcomes of patients with schizophrenia 
remained poor7.  
 
 
A number of studies have explored a biological basis for this observed association between 
schizophrenia and cardiovascular disease and risk factors14. The over-arching theme seems to 
be related to systems inflammation where multiple pro-inflammatory cytokines are recognized 
to be altered in patients with schizophrenia. This state of immune dysregulation has been shown 
to be damaging to neuronal and microglial cells15, but also to form the basis for the 
development of insulin resistance, metabolic syndrome and other risk factors that are causative 
of atherosclerosis14. In addition to this, anti-psychotic medications have been implicated in 
pathological oxidative stress which is implicated in further compounding the dysregulated 
inflammatory response to tissue damage16.  
 
 
The observations in the study by Attar et al6 serve to strengthen the hypothesis of an 
interplay between schizophrenia and acute coronary syndrome. It highlights an exciting area 
of research where collaborative spirit between multiple disciplines (cardiology, epidemiology, 
neuropsychiatry and others) can be fostered to advance this area of research. Perhaps it is time 
for prospective cohort studies to be commissioned, where matching could take place in a more 
controlled fashion with rigorous follow up and measurement of co-morbid factors as well as 
biomarkers. Until then, both physicians and psychiatrists must weigh the increasing evidence 
that recognizes this interplay, and use their clinical judgement to tackle it. Specifically, efforts 
should be intensified to provide tailored education and management advice on diet, smoking 
cessation, weight management and physical activity. In addition, reviews of antipsychotic 
medications should take place on a regular basis in an attempt to choose the agent/dosage with 
the least possible physical side effects. Finally, the observation of reduced revascularisation 
rates in this patient group must be reviewed and tackled by tailoring revascularisation 
strategies, follow up and cardiac rehabilitation arrangements as well as intensifying efforts to 
manage risk factors by engaging with primary care services and keeping a closer eye on this 
high risk group13.  
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